Trial Profile

A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TT 125 802 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Acronyms TT-CSP-001
Sponsors TOLREMO therapeutics

Most Recent Events

04 Jun 2025 According to TOLREMO therapeutics media release, the data from this study has been presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting.
21 May 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
21 May 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Aug 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com